Flightless I Technology
Flightless I is a novel drug target that regulates important cellular behaviours including mobility, contraction, adhesion, proliferation and cytokine production. The activity of Flightless I is mediated through interaction with components of the cell’s cytoskeleton, modulation of intracellular signalling pathways and regulation of cellular transcription events.
Flightless I is a negative regulator of the migratory and proliferative events of tissue repair. Inhibition of Flightless I using antibodies has been shown to improve wound repair in murine and porcine models of normal and compromised wound healing and a murine model of Epidermolysis Bullosa.
In addition, anti-flightless antibodies have been shown to reduce the incidence and growth of skin tumours in a mouse model of squamous cell carcinoma.
AbRegen Board and Management
Professor Allison Cowin
Founder, Chief Scientific Officer and Board Member
Dr Prashanth Rajan
Dr Viraj Perera
Non-executive Board Member
Dr David Belford
Chairman of the Board
Therapeutic antibodies for regenerative medicine.
AbRegen is a preclinical stage biotechnology company that specialises in the development of antibody-based therapeutics for tissue repair applications.